At present, therapies in the Non-small cell lung cancer market are Opdivo (Nivolumab), Imfinzi (Durvalumab), Keytruda (Pembrolizumab), Tecentriq (Atezolizumab), Tagrisso (osimertinib), Vizimpro (dacomitinib) and others.